Fujiwara H, Shima J, Sano H, Kosugi A, Nakajima H, Hamaoka T
Department of Oncogenesis, Osaka University Medical School, Japan.
Prog Clin Biol Res. 1987;244:335-44.
The theoretical basis and practical manipulation of cellular collaboration mechanism responsible for enhanced induction of tumor-specific immunotherapeutic potential were reviewed. Enhanced generation of tumor-specific in vivo protective immunity could be obtained by immunizing tumor cells coupling highly immunogenic additional antigens to hosts in which helper T cell activity against these antigens is already induced. MDP haptens newly synthesized exhibited cross-reactivity with BCG and functioned as appropriate tumor cell-modifying reagents in BCG-sensitized individuals. With the use of these new MDP haptens, the above approach for enhanced tumor immunity was successfully applied to tumor-specific immunotherapy models. When tumor-bearing hosts had been sensitized to BCG, the growth of tumor cells in a solid tumor mass or in metastasized or disseminated form were effectively inhibited by active immunization with MDP hapten-modified tumor cells. Thus, these results reinforce the theoretical framework of the approach for enhanced induction of tumor immunity. The protocols which were developed in these studies also provide an effective maneuver for tumor-specific immunotherapy.
本文综述了负责增强肿瘤特异性免疫治疗潜力的细胞协作机制的理论基础和实际操作。通过将高度免疫原性的附加抗原偶联到肿瘤细胞上，并将其免疫给已经诱导出针对这些抗原的辅助性T细胞活性的宿主，可以在体内增强肿瘤特异性保护性免疫的产生。新合成的MDP半抗原与卡介苗表现出交叉反应，并在卡介苗致敏个体中作为合适的肿瘤细胞修饰试剂发挥作用。使用这些新的MDP半抗原，上述增强肿瘤免疫的方法成功应用于肿瘤特异性免疫治疗模型。当荷瘤宿主对卡介苗致敏时，用MDP半抗原修饰的肿瘤细胞进行主动免疫可有效抑制实体瘤肿块中或转移或播散形式的肿瘤细胞生长。因此，这些结果强化了增强肿瘤免疫诱导方法的理论框架。这些研究中开发的方案也为肿瘤特异性免疫治疗提供了一种有效的策略。
